Corticosteroids in the management of acute multiple sclerosis exacerbations

Compston A, Coles A (2008) Multiple sclerosis. Lancet 372(9648):1502–1517. doi:10.1016/S0140-6736(08)61620-7 Confavreux C, Vukusic S (2006) Natural history of multiple sclerosis: a unifying concept. Brain 129(Pt 3):606–616. doi:10.1093/brain/awl007 Scalfari A, Neuhaus A, Degenhardt A, Rice GP, Muraro PA, Daumer M, Ebers GC (2010) The natural history of multiple sclerosis: a geographically based study 10: relapses and long-term disability. Brain 133(Pt 7):1914–1929. doi:10.1093/brain/awq118 Frohman EM, Shah A, Eggenberger E, Metz L, Zivadinov R, Stuve O (2007) Corticosteroids for multiple sclerosis: I. Application for treating exacerbations. NeuroTherapeutics 4(4):618–626. doi:10.1016/j.nurt.2007.07.008 Stahn C, Lowenberg M, Hommes DW, Buttgereit F (2007) Molecular mechanisms of glucocorticoid action and selective glucocorticoid receptor agonists. Mol Cell Endocrinol 275(1–2):71–78. doi:10.1016/j.mce.2007.05.019 Sloka JS, Stefanelli M (2005) The mechanism of action of methylprednisolone in the treatment of multiple sclerosis. Mult Scler 11(4):425–432 Galon J, Franchimont D, Hiroi N, Frey G, Boettner A, Ehrhart-Bornstein M, O’Shea JJ, Chrousos GP, Bornstein SR (2002) Gene profiling reveals unknown enhancing and suppressive actions of glucocorticoids on immune cells. FASEB J 16(1):61–71. doi:10.1096/fj.01-0245com Almawi WY, Beyhum HN, Rahme AA, Rieder MJ (1996) Regulation of cytokine and cytokine receptor expression by glucocorticoids. J Leukoc Biol 60(5):563–572 Martinez-Caceres EM, Barrau MA, Brieva L, Espejo C, Barbera N, Montalban X (2002) Treatment with methylprednisolone in relapses of multiple sclerosis patients: immunological evidence of immediate and short-term but not long-lasting effects. Clin Exp Immunol 127(1):165–171 Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, Fujihara K, Havrdova E, Hutchinson M, Kappos L, Lublin FD, Montalban X, O’Connor P, Sandberg-Wollheim M, Thompson AJ, Waubant E, Weinshenker B, Wolinsky JS (2011) Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 69(2):292–302. doi:10.1002/ana.22366 Guthrie TC, Nelson DA (1995) Influence of temperature changes on multiple sclerosis: critical review of mechanisms and research potential. J Neurol Sci 129(1):1–8 D’Hooghe MB, Nagels G, Bissay V, De Keyser J (2010) Modifiable factors influencing relapses and disability in multiple sclerosis. Mult Scler 16(7):773–785. doi:10.1177/1352458510367721 Correale J, Fiol M, Gilmore W (2006) The risk of relapses in multiple sclerosis during systemic infections. Neurology 67(4):652–659. doi:10.1212/01.wnl.0000233834.09743.3b Mohr DC, Hart SL, Julian L, Cox D, Pelletier D (2004) Association between stressful life events and exacerbation in multiple sclerosis: a meta-analysis. BMJ 328(7442):731. doi:10.1136/bmj.38041.724421.55 Filippini G, Brusaferri F, Sibley WA, Citterio A, Ciucci G, Midgard R, Candelise L (2000) Corticosteroids or ACTH for acute exacerbations in multiple sclerosis. Cochrane Database Syst Rev 4:CD001331. doi:10.1002/14651858.CD001331 Rose AS, Kuzma JW, Kurtzke JF, Namerow NS, Sibley WA, Tourtellotte WW (1970) Cooperative study in the evaluation of therapy in multiple sclerosis. ACTH vs. placebo—final report. Neurology 20(5):1–59 Brusaferri F, Candelise L (2000) Steroids for multiple sclerosis and optic neuritis: a meta-analysis of randomized controlled clinical trials. J Neurol 247(6):435–442 Miller DM, Weinstock-Guttman B, Bethoux F, Lee JC, Beck G, Block V, Durelli L, LaMantia L, Barnes D, Sellebjerg F, Rudick RA (2000) A meta-analysis of methylprednisolone in recovery from multiple sclerosis exacerbations. Mult Scler 6(4):267–273 Ramo-Tello C, Tintore M, Rovira A, Ramio-Torrenta L, Brieva L, Saiz A, Cano A, Carmona O, Hervas JV, Grau-Lopez L (2016) Baseline clinical status as a predictor of methylprednisolone response in multiple sclerosis relapses. Mult Scler 22(1):117–121. doi:10.1177/1352458515590648 Beck RW, Cleary PA, Anderson MM Jr, Keltner JL, Shults WT, Kaufman DI, Buckley EG, Corbett JJ, Kupersmith MJ, Miller NR et al (1992) A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. The Optic Neuritis Study Group. N Engl J Med 326(9):581–588. doi:10.1056/NEJM199202273260901 Beck RW, Cleary PA, Trobe JD, Kaufman DI, Kupersmith MJ, Paty DW, Brown CH (1993) The effect of corticosteroids for acute optic neuritis on the subsequent development of multiple sclerosis. The Optic Neuritis Study Group. N Engl J Med 329(24):1764–1769. doi:10.1056/NEJM199312093292403 Goodin DS (1999) Perils and pitfalls in the interpretation of clinical trials: a reflection on the recent experience in multiple sclerosis. Neuroepidemiology 18(2):53–63. doi:10.1159/000069408 Sellebjerg F, Frederiksen JL, Nielsen PM, Olesen J (1998) Double-blind, randomized, placebo-controlled study of oral, high-dose methylprednisolone in attacks of MS. Neurology 51(2):529–534 Miller H, Newell DJ, Ridley A (1961) Multiple sclerosis. Treatment of acute exacerbations with corticotrophin (A.C.T.H.). Lancet 2(7212):1120–1122 Durelli L, Cocito D, Riccio A, Barile C, Bergamasco B, Baggio GF, Perla F, Delsedime M, Gusmaroli G, Bergamini L (1986) High-dose intravenous methylprednisolone in the treatment of multiple sclerosis: clinical-immunologic correlations. Neurology 36(2):238–243 Milligan NM, Newcombe R, Compston DA (1987) A double-blind controlled trial of high dose methylprednisolone in patients with multiple sclerosis: 1. Clinical effects. J Neurol Neurosurg Psychiatry 50(5):511–516 Filipovic SR, Drulovic J, Stojsavljevic N, Levic Z (1997) The effects of high-dose intravenous methylprednisolone on event-related potentials in patients with multiple sclerosis. J Neurol Sci 152(2):147–153 La Mantia L, Eoli M, Milanese C, Salmaggi A, Dufour A, Torri V (1994) Double-blind trial of dexamethasone versus methylprednisolone in multiple sclerosis acute relapses. Eur Neurol 34(4):199–203 Milanese C, La Mantia L, Salmaggi A, Campi A, Eoli M, Scaioli V, Nespolo A, Corridori F (1989) Double-blind randomized trial of ACTH versus dexamethasone versus methylprednisolone in multiple sclerosis bouts. Clinical, cerebrospinal fluid and neurophysiological results. Eur Neurol 29(1):10–14 Tandon R, Verma K, Chawla B, Sharma N, Titiyal JS, Kalaivani M, Vajpayee RB (2009) Intravenous dexamethasone vs methylprednisolone pulse therapy in the treatment of acute endothelial graft rejection. Eye 23(3):635–639. doi:10.1038/eye.2008.25 Thompson AJ, Kennard C, Swash M, Summers B, Yuill GM, Shepherd DI, Roche S, Perkin GD, Loizou LA, Ferner R et al (1989) Relative efficacy of intravenous methylprednisolone and ACTH in the treatment of acute relapse in MS. Neurology 39(7):969–971 Burton JM, O’Connor PW, Hohol M, Beyene J (2012) Oral versus intravenous steroids for treatment of relapses in multiple sclerosis. Cochrane Database Syst Rev 12:CD006921. doi:10.1002/14651858.CD006921.pub3 Le Page E, Veillard D, Laplaud DA, Hamonic S, Wardi R, Lebrun C, Zagnoli F, Wiertlewski S, Deburghgraeve V, Coustans M, Edan G, investigators C, West Network for Excellence in N (2015) Oral versus intravenous high-dose methylprednisolone for treatment of relapses in patients with multiple sclerosis (COPOUSEP): a randomised, controlled, double-blind, non-inferiority trial. Lancet 386(9997):974–981. doi:10.1016/S0140-6736(15)61137-0 Ramo-Tello C, Grau-Lopez L, Tintore M, Rovira A, Ramio I, Torrenta L, Brieva L, Cano A, Carmona O, Saiz A, Torres F, Giner P, Nos C, Massuet A, Montalban X, Martinez-Caceres E, Costa J (2014) A randomized clinical trial of oral versus intravenous methylprednisolone for relapse of MS. Mult Scler 20(6):717–725. doi:10.1177/1352458513508835 Martinelli V, Rocca MA, Annovazzi P, Pulizzi A, Rodegher M, Martinelli Boneschi F, Scotti R, Falini A, Sormani MP, Comi G, Filippi M (2009) A short-term randomized MRI study of high-dose oral vs intravenous methylprednisolone in MS. Neurology 73(22):1842–1848. doi:10.1212/WNL.0b013e3181c3fd5b Morrow SA, Stoian CA, Dmitrovic J, Chan SC, Metz LM (2004) The bioavailability of IV methylprednisolone and oral prednisone in multiple sclerosis. Neurology 63(6):1079–1080 Grau-Lopez L, Teniente-Serra A, Tintore M, Rovira A, Ramio-Torrenta L, Brieva L, Saiz A, Cano A, Carmona O, Hervas JV, Martinez-Caceres EM, Ramo-Tello C (2015) Similar biological effect of high-dose oral versus intravenous methylprednisolone in multiple sclerosis relapses. Mult Scler 21(5):646–650. doi:10.1177/1352458514546786 Comi G, Radaelli M (2015) Oral corticosteroids for multiple sclerosis relapse. Lancet 386(9997):937–939. doi:10.1016/S0140-6736(15)00072-0 Kister I, Corboy JR (2016) Reducing costs while enhancing quality of care in MS. Neurology 87(15):1617–1622. doi:10.1212/WNL.0000000000003113 Alam SM, Kyriakides T, Lawden M, Newman PK (1993) Methylprednisolone in multiple sclerosis: a comparison of oral with intravenous therapy at equivalent high dose. J Neurol Neurosurg Psychiatry 56(11):1219–1220 Barnes D, Hughes RA, Morris RW, Wade-Jones O, Brown P, Britton T, Francis DA, Perkin GD, Rudge P, Swash M, Katifi H, Farmer S, Frankel J (1997) Randomised trial of oral and intravenous methylprednisolone in acute relapses of multiple sclerosis. Lancet 349(9056):902–906 Caster O, Edwards IR (2015) Quantitative benefit-risk assessment of methylprednisolone in multiple sclerosis relapses. BMC Neurol 15:206. doi:10.1186/s12883-015-0450-x Levic Z, Micic D, Nikolic J, Stojisavljevic N, Sokic D, Jankovic S, Kendereski A, Mavra M (1996) Short-term high dose steroid therapy does not affect the hypothalamic-pituitary-adrenal axis in relapsing multiple sclerosis patients. Clinical assessment by the insulin tolerance test. J Endocrinol Invest 19(1):30–34. doi:10.1007/BF03347855 Visser LH, Beekman R, Tijssen CC, Uitdehaag BM, Lee ML, Movig KL, Lenderink AW (2004) A randomized, double-blind, placebo-controlled pilot study of i.v. immune globulins in combination with i.v. methylprednisolone in the treatment of relapses in patients with MS. Mult Scler 10(1):89–91 Iuliano G, Napoletano R, Esposito A (2008) Multiple sclerosis: relapses and timing of remissions. Eur Neurol 59(1–2):44–48. doi:10.1159/000109260 Confavreux C, O’Connor P, Comi G, Freedman MS, Miller AE, Olsson TP, Wolinsky JS, Bagulho T, Delhay JL, Dukovic D, Truffinet P, Kappos L, TT Group (2014) Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol 13(3):247–256. doi:10.1016/S1474-4422(13)70308-9 Fox RJ, Miller DH, Phillips JT, Hutchinson M, Havrdova E, Kita M, Yang M, Raghupathi K, Novas M, Sweetser MT, Viglietta V, Dawson KT, CS Investigators (2012) Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med 367(12):1087–1097. doi:10.1056/NEJMoa1206328 Mikol DD, Barkhof F, Chang P, Coyle PK, Jeffery DR, Schwid SR, Stubinski B, Uitdehaag B, Rs group (2008) Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the rebif vs glatiramer acetate in relapsing MS disease [REGARD] study): a multicentre, randomised, parallel, open-label trial. Lancet Neurol 7(10):903–914. doi:10.1016/S1474-4422(08)70200-X Cohen JA, Coles AJ, Arnold DL, Confavreux C, Fox EJ, Hartung HP, Havrdova E, Selmaj KW, Weiner HL, Fisher E, Brinar VV, Giovannoni G, Stojanovic M, Ertik BI, Lake SL, Margolin DH, Panzara MA, Compston DA, Clinical and Medical Investigations (2012) Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet 380(9856):1819–1828. doi:10.1016/S0140-6736(12)61769-3 Investigators CT, Coles AJ, Compston DA, Selmaj KW, Lake SL, Moran S, Margolin DH, Norris K, Tandon PK (2008) Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N Engl J Med 359(17):1786–1801. doi:10.1056/NEJMoa0802670 Polman CH, O’Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH, Phillips JT, Lublin FD, Giovannoni G, Wajgt A, Toal M, Lynn F, Panzara MA, Sandrock AW, Investigators A (2006) A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 354(9):899–910. doi:10.1056/NEJMoa044397 Miller DH, Fazekas F, Montalban X, Reingold SC, Trojano M (2014) Pregnancy, sex and hormonal factors in multiple sclerosis. Mult Scler 20(5):527–536. doi:10.1177/1352458513519840 Vukusic S, Marignier R (2015) Multiple sclerosis and pregnancy in the ‘treatment era’. Nat Rev Neurol 11(5):280–289. doi:10.1038/nrneurol.2015.53 Houtchens MK, Kolb CM (2013) Multiple sclerosis and pregnancy: therapeutic considerations. J Neurol 260(5):1202–1214. doi:10.1007/s00415-012-6653-9 Lyons PR, Newman PK, Saunders M (1988) Methylprednisolone therapy in multiple sclerosis: a profile of adverse effects. J Neurol Neurosurg Psychiatry 51(2):285–287 Carpani de Kaski M, Rentsch R, Levi S, Hodgson HJ (1995) Corticosteroids reduce regenerative repair of epithelium in experimental gastric ulcers. Gut 37(5):613–616 Guslandi M, Tittobello A (1992) Steroid ulcers: a myth revisited. BMJ 304(6828):655–656 Poetker DM, Reh DD (2010) A comprehensive review of the adverse effects of systemic corticosteroids. Otolaryngol Clin North Am 43(4):753–768. doi:10.1016/j.otc.2010.04.003 Warrington TP, Bostwick JM (2006) Psychiatric adverse effects of corticosteroids. Mayo Clin Proc 81(10):1361–1367. doi:10.4065/81.10.1361 McLuckie AE, Savage RW (1993) Atrial fibrillation following pulse methylprednisolone therapy in an adult. Chest 104(2):622–623 Moretti R, Torre P, Antonello RM, Zorzon M, Cazzato G (2000) Recurrent atrial fibrillation associated with pulse administration of high doses of methylprednysolone: a possible prophylactic treatment. Eur J Neurol 7(1):130 Caster O, Conforti A, Viola E, Edwards IR (2014) Methylprednisolone-induced hepatotoxicity: experiences from global adverse drug reaction surveillance. Eur J Clin Pharmacol 70(4):501–503. doi:10.1007/s00228-013-1632-3 Gutkowski K, Chwist A, Hartleb M (2011) Liver injury induced by high-dose methylprednisolone therapy: a case report and brief review of the literature. Hepat Mon 11(8):656–661 Lopez-Serrano MC, Moreno-Ancillo A, Contreras J, Ortega N, Cabanas R, Barranco P, Munoz-Pereira M (1996) Two cases of specific adverse reactions to systemic corticosteroids. J Investig Allergol Clin Immunol 6(5):324–327 Tuzun S, Altintas A, Karacan I, Tangurek S, Saip S, Siva A (2003) Bone status in multiple sclerosis: beyond corticosteroids. Mult Scler 9(6):600–604 Zorzon M, Zivadinov R, Locatelli L, Giuntini D, Toncic M, Bosco A, Nasuelli D, Bratina A, Tommasi MA, Rudick RA, Cazzato G (2005) Long-term effects of intravenous high dose methylprednisolone pulses on bone mineral density in patients with multiple sclerosis. Eur J Neurol 12(7):550–556. doi:10.1111/j.1468-1331.2005.00988.x Sahraian MA, Yadegari S, Azarpajouh R, Forughipour M (2012) Avascular necrosis of the femoral head in multiple sclerosis: report of five patients. Neurol Sci 33(6):1443–1446. doi:10.1007/s10072-011-0914-8 Costedoat-Chalumeau N, Amoura Z, Aymard G, Sevin O, Wechsler B, Cacoub P, Du LT, Diquet B, Ankri A, Piette JC (2000) Potentiation of vitamin K antagonists by high-dose intravenous methylprednisolone. Ann Intern Med 132(8):631–635 Hazlewood KA, Fugate SE, Harrison DL (2006) Effect of oral corticosteroids on chronic warfarin therapy. Ann Pharmacother 40(12):2101–2106. doi:10.1345/aph.1H418 Varis T, Kivisto KT, Neuvonen PJ (2000) The effect of itraconazole on the pharmacokinetics and pharmacodynamics of oral prednisolone. Eur J Clin Pharmacol 56(1):57–60 Weinshenker BG, O’Brien PC, Petterson TM, Noseworthy JH, Lucchinetti CF, Dodick DW, Pineda AA, Stevens LN, Rodriguez M (1999) A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. Ann Neurol 46(6):878–886 Klingel R, Heibges A, Fassbender C (2009) Plasma exchange and immunoadsorption for autoimmune neurologic diseases—current guidelines and future perspectives. Atheroscler Suppl 10(5):129–132. doi:10.1016/S1567-5688(09)71827-6